Published online Feb 6, 2016. doi: 10.4292/wjgpt.v7.i1.1
Peer-review started: May 30, 2015
First decision: August 14, 2015
Revised: September 8, 2015
Accepted: November 3, 2015
Article in press: November 4, 2015
Published online: February 6, 2016
Processing time: 246 Days and 11.4 Hours
Proton pump inhibitors (PPIs) represent one of the most extensively prescribed classes of drugs in general and in patients with liver cirrhosis. Many prescriptions are made without a clear adherence to standard indications. As a class of ordinarily well tolerated drug, PPIs are not free of side-effects and concerns have been raised about a possible role for PPIs in predisposing patients to an increased risk of bacterial infections and sepsis. As evidences of different power are accumulating on this topic, prospective studies are needed to reach a more universal agreement, but definitely more attention is needed by prescribers in being more adherent to the few recognized indications for the use of PPIs, particularly in patients with liver cirrhosis. Otherwise, doctors could run the risk of being accused of “abused” prescription.
Core tip: Many prescriptions of proton pump inhibitors (PPIs) are made without adhering to standard recognized indications. PPIs are ordinarily well tolerated but are not free of side-effects, and, in patients with liver cirrhosis, concerns are accruing on a possible role for PPIs in increasing the risk of infections and sepsis. As evidences of different power are accumulating, prospective studies are needed. However, prescribers should put definitely more attention in adhering to the recognized indications for the use of PPIs, especially in patients with cirrhosis. Otherwise, doctors could be responsible for “abuse” of prescription.